Abstract

Atopic dermatitis is a chronic inflammatory disease that arises from polygenic disposition, a dysfunction of the physicochemical epithelial barrier, a cutaneous dysbiosis, and a faulty neurosensory activity and shows a highly individual acuity due to epigenetic factors. An essential component of therapeutic management is the application of anti-inflammatory topical medication. Currently, topical glucocorticoids and topical calcineurin inhibitors are routinely used in reactive and proactive therapy. In recent years, the development of molecular medicine has identified several new therapeutic targets that have enabled the development of innovative therapeutic approaches. In addition to phosphodiesterase-4 inhibitors and aryl hydrocarbon receptor modulators, it is mainly Janus kinase inhibitors with different selectivity that are emerging as new effective and safe options for topical therapy. The current data suggests that in the coming months and years representatives of the above-mentioned substance classes will be approved for topical use.

Author Details

Authors

• Johannes Wohlrab¹,²
• Burkhard Kreft¹
• Luisa Sophie Scholz²

Departments

• ¹ University Hospital Halle (Saale), Clinic for Dermatology and Venereology, and
• ² Institute for Applied Dermatopharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany

Address

Prof. Dr. Johannes Wohlrab, Klinik für Dermatologie und Venerologie, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Straße 40, Halle (Saale), Germany
Email: [email protected]

Citation